Trans-Arterial Chemo-Embolization (TACE) vs TACE Plus Stereotactic Body Radio Therapy (SBRT) in the Treatment of Hepatocellular Carcinoma (HCC)
Trans-Arterial Chemo-Embolization (TACE) vs TACE Plus Stereotactic Body Radio Therapy (SBRT) in the Treatment of Hepatocellular Carcinoma (HCC)
This randomized phase II trial studies how well transarterial chemoembolization (TACE) works compared with TACE plus radiation therapy in treating patients with end stage liver disease, liver tumors, or potential liver transplant candidates. TACE involves reaching up to the blood vessel that feeds the tumor through a catheter placed into the groin vessel. Once the physician has defined the vessel going to the tumor, chemotherapy is infused to the tumor and the vessel is blocked, maintaining the chemotherapy for longer time inside the tumor and stopping the blood flow that feeds the tumor. Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that delivers radiation to the tumor cells but does not harm normal liver cells. It is not yet known whether TACE is more effective with or without SBRT in treating liver tumors.
PRIMARY OBJECTIVES:
I. To determine in patients with stage A to C hepatocellular carcinoma, if stereotactic body radiotherapy after TACE enhanced the response rate of hepatocellular carcinoma (HCC) when compared to TACE alone at 3 months.
SECONDARY OBJECTIVES:
I. To determine in patients with stage A to C hepatocellular carcinoma, if TACE plus SBRT can achieve a downstaging rate of >= 30% at 3 and 6 months.
II. To determine the rate of grade 3 or 4 adverse events associated with SBRT for liver tumors.
III. To determine the rate of local progression after SBRT. (Based on Response Evaluation Criteria in Solid Tumors [RECIST] criteria) IV. Number of patients who achieve liver transplantation. V. Overall survival.
OUTLINE: Patients are randomized to 1 of 2 treatment arms after the first loco-regional therapy with TACE.
ARM I: Patients undergo TACE according to institutional standard with doxorubicin-eluting beads.
ARM II: Patients undergo TACE as in Arm I and 3 or 5 fractions of SBRT given at least 48 hours apart over 14 days.
After completion of study treatment, patients are followed up at 1, 3, and 6 months and then periodically thereafter.
Inclusion Criteria:
HCC is staged as Barcelona A to C
Treatment with SBRT can occur within 6 weeks of registration
Eastern Cooperative Oncology Group (ECOG) performance status =< 2
Patient has
Hemoglobin greater than 10.0 g/dL
Total bilirubin less than 3.0 mg/dL
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 X institutional upper limit of normal
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 X institutional upper limit of normal
Total aggregate of maximal dimension of liver tumors is =< 8 cm
Cirrhotic patients Child Pugh class A or B (score =< 7)
Patient must be determined by the treating physician to be medically eligible for liver transplantation measured by imaging modality (magnetic resonance imaging [MRI]/computed tomography [CT] scan) three months post final treatment
Absolute neutrophil count >= 1,500/μl
Platelet count >= 50,000 μl (after transfusion if required)
Life expectancy > 12 weeks
Subjects must have the ability to understand and be willing to provide written informed consent
Women of child-bearing potential must have a negative pregnancy test within 4 weeks to the start of the SBRT treatment
Women must not be pregnant or nursing
Sexually active women must agree to use accepted forms of birth control; acceptable options for birth control will be documented in the consent and discussed with the subject prior to enrollment
Exclusion Criteria: